The Food and Drug Administration Friday issued warning letters to all three duodenoscope manufacturers for failing to comply with a 2015 order to conduct postmarket surveillance studies to determine whether health care facilities are able to properly clean and disinfect the devices. “The FDA has taken important steps to improve the reprocessing of duodenoscopes, and we’ve seen a reduction in reports of patient infections, but we need the required postmarket studies to determine whether these measures are being properly implemented in real-world clinical settings and whether we need to take additional action to further improve the safety of these devices,” said Jeff Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “We expect these device manufacturers to meet their study obligations to ensure patient safety.” The letters were sent to Olympus, Fujifilm and Pentax, who are expected to submit a plan by March 24 outlining how study milestones will be achieved.

Related News Articles

Perspective
In Michigan, African Americans make up 14% of the population … but account for 40% of the COVID-19 deaths. In Chicago: 30% of the population … and 46% of the…
Headline
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related…
Headline
Hospitals and health systems continue to provide care for our most vulnerable communities by addressing social needs, educating on COVID-19 risks and…
Headline
A study of 305 hospitalized adult COVID-19 patients in Georgia found an overrepresentation of black patients, with over a quarter lacking known risk factors,…
Blog
The AHA is committed to ensuring that all people, regardless of background or zip code, have equitable access to quality health care. As the COVID-19 pandemic…
Headline
The AHA’s Institute for Diversity and Health Equity today released a new resource highlighting steps hospitals can and are taking to address disparities that…